We and our partner, Alnylam, education books established Regulus Therapeutics Inc, a company that is focused on the discovery, development and commercialization of microRNA-based therapeutics. In 2012, Regulus completed an initial public offering and is traded on The NASDAQ Global Market under the symbol RGLS.
In addition, we have satellite company partnerships focused on developing and advancing certain RNA-based therapeutic technologies. These partnerships take advantage of our dominant intellectual property estate and leverage our own investments in our core technologies. Typically a cross license between us and our partner allows us to participate in newly emerging approaches to RNA-bassatellite companies Isis Pharmaceuticalsed therapeutics that augment our active programs in these areas.
We expand the reach and potential of our RNA-based therapeutics into disease areas that are outside of our core focus areas through our drug discovery and development satellite company partners. Our satellite company partners have resources and expertise that are focused in a particular disease area and share the common goal of advancing our drugs. In these partnerships, we typically own equity in the company, dress2302.typepad.com often as part of the licensing agreement, and we also retain the potential to earn milestone payments and royalties. Our satellite company strategy allows us to create and support a much broader product pipeline than we could develop on our own.
Our mission is to provide antisense drugs to patients with significant unmet medical needs.
Learn More
Learn More
We know that sick people depend on us,Australian Gamer. and we have the technology to change the way diseases are treated.
Learn More
KYNAMRO is a trademark of Genzyme Corporation.
is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.
education fund